DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3

Recruiting

Conditions: Lung Cancer, Non-squamous, Non-small Cell

Interventions: Drug: pembrolizumab
Drug: zongertinib
Drug: cisplatin
Drug: carboplatin
Drug: pemetrexed

First Posted Date: 2023-11-30

Last Posted Date: 2025-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 416

Registration Number: NCT06151574

Locations: 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Mohtaseb Cancer Center and Blood Disorders, LLC, Bullhead City, Arizona, United States
🇺🇸
Precision NextGen Oncology, Beverly Hills, California, United States

and more 164 locations

A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1584862
Drug: Placebo

First Posted Date: 2023-11-28

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT06148948

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 765845
Drug: Placebo

First Posted Date: 2023-11-18

Last Posted Date: 2023-11-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 92

Registration Number: NCT06139315

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

Phase 2

Recruiting

Conditions: Myocardial Infarction

Interventions: Drug: Placebo matching BI 765845
Drug: BI 765845

First Posted Date: 2023-11-18

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 350

Registration Number: NCT06139328

Locations: 🇺🇸
Flourish Research - Los Angeles (Covina) Clinical Research, Covina, California, United States
🇺🇸
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Colorado Heart and Vascular PC, Golden, Colorado, United States

and more 95 locations

A Study to Test How Different Doses of BI 1015550 Are Taken up in the Body of Healthy Japanese Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550

First Posted Date: 2023-11-18

Last Posted Date: 2024-03-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT06139302

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 765845 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 765845
Drug: Placebo

First Posted Date: 2023-11-18

Last Posted Date: 2024-01-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT06139341

Locations: 🇯🇵
Clinical Research Hospital Tokyo, Tokyo, Shinjuku-ku, Japan

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Phase 1

Recruiting

Conditions: Neuroendocrine Neoplasms

Interventions: Drug: BI 764532
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2023-11-15

Last Posted Date: 2025-05-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 55

Registration Number: NCT06132113

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain

and more 18 locations

Real-world Study of Dedifferentiated Liposarcoma Patients in China

Completed

Conditions: Dedifferentiated Liposarcoma

First Posted Date: 2023-11-03

Last Posted Date: 2024-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1390

Registration Number: NCT06115681

Locations: 🇨🇳
Beijing Jishuitan hospital, Beijing, China

A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2023-10-30

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 46

Registration Number: NCT06107036

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Phase 1

Recruiting

Conditions: Gastrointestinal Cancer
Lung Cancer
Pancreatic Cancer
Colorectal Cancer
Head and Neck Cancer
Liver Cancer

Interventions: Drug: BI 765049
Drug: Ezabenlimab

First Posted Date: 2023-10-23

Last Posted Date: 2025-05-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 70

Registration Number: NCT06091930

Locations: 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳
Shanghai East Hospital, Shanghai, China
🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy